

# Scaling new heights in breast cancer care

Saturday 20 October 2018, 18:30–20:00

ICM - Room 1, Messe Munich, Munich, Germany



## Dear Colleagues,

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium '**Scaling new heights in breast cancer care**'. The symposium will be held on **Saturday 20 October** from **18:30** to **20:00**, during the ESMO 2018 Congress.

The treatment landscape for advanced breast cancer has rapidly evolved over the years, and targeted therapies are further transforming the treatment paradigm as our clinical experience continues to grow. However, despite these advances, significant unmet needs still exist in treating patients with advanced disease.

During our symposium, our expert faculty will review the latest evidence for the treatment of HR+/HER2-metastatic breast cancer and discuss how to optimise outcomes for patients treated with CDK4/6 inhibitors in the clinic. In addition, we will discuss recent advances in the clinical development of PARP inhibitors, and provide an overview of key areas of ongoing research that we hope will lead to improved outcomes for patients with breast cancer in the near future.

I look forward to welcoming you in Munich for what promises to be an informative and engaging symposium, as we set out to scale new heights in breast cancer care together.

**Nadia Harbeck, Chair**

Breast Center, Dept. OB & GYN, University of Munich (LMU), Munich, Germany

## Programme

Chair: Nadia Harbeck (Germany)

<b>18:30–18:40</b>	Breast cancer management: Progress so far and the journey ahead	<b>Nadia Harbeck, Chair (Germany)</b>
<b>18:40–19:00</b>	Leading the way in the treatment of HR+/HER2-advanced breast cancer	<b>Massimo Cristofanilli (USA)</b>
<b>19:00–19:20</b>	Navigating the path: Optimising the management of CDK4/6 inhibitors in practice	<b>Giuseppe Curigliano (Italy)</b>
<b>19:20–19:40</b>	What's on the horizon? Evolving treatment paradigms in breast cancer care	<b>Johannes Ettl (Germany)</b>
<b>19:40–20:00</b>	Q&A and closing remarks	<b>Nadia Harbeck, Chair (Germany)</b>